5Diez M,Torres A, Maestro ML,et al. Prediction of survival and recurrence by serum and cytosollc levels of CEA, CA125 and SCC antigens in resectable non-small-cell lung cancer. Br J Cancer, 1996,10(8) : 1248-1254.
6Diez M, Torres A, Pollan M, et al. Prognostic significance of serum CA125 antigen assay in patient with non small cell lung cancer. Cancer, 1994,73(5) : 1368-1376.
7Plavec G, Ninkovic M, Kozlovacki G, et al. Tumor maker sinpleural effusion sinbronchogenic carcinoma and tuberculosis.Vojnosanit Pregl, 2002,59 (1) : 23.
9Sawabata N, Ohta M, Takeda S, et al. Serum carcinoembryonic antigen level in surgical lyresected clinical stage in patient switch non-small cell lung cancer. Ann Thorac Surg, 2002,74(1):174.
10D'Cunha J,Corfits AL, Herndon JE, et al. Molecular staging of lung cancer: real-time polymerase chain reaction estimation of lymphnode micrometastatic tumor cell lung cancer-preliminary results of Cancer and Leukemia GroupB Trial 9761. J Thorac Cardiovasc Surg, 2002,123 (3) : 484.
3Vincent RG,Chu-TM,Lane-WW.The value of CEA in patients with carcinoma of the lung.Cancer,1979,44:685
4尹伯元主编.放射免疫分析在医学中的应用.北京:原子能出版社,1991,328-331
5Muraki M,Tohda Y,Iwanaga T,et al.Assessment of serum CYFRA21-1 in lung cancer.Cancer,1996,77(7):1274～1277
6Brechot JM,Chevret S,Nataf J,et al.Diagnostic and prognostic value of Cyfra21-1 compared with other tumor markers in patients with non-small cell lung cancer:a prospective study of 116patients.Eur J Cancer,1997,33 (3):385～391
